NASDAQ:OLMA Olema Pharmaceuticals Q3 2026 Earnings Results & Report $7.31 -0.05 (-0.68%) As of 02:18 PM Eastern This is a fair market value price provided by Massive. Learn more. Olema Pharmaceuticals missed analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.73 versus the -$0.6368 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeAfter Market ClosesConference Call7:00 AM ET Olema Pharmaceuticals EPS ResultsActual EPS-$0.73Consensus EPS -$0.6368Beat/MissMissed by -$0.0932One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersOlema Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$1.25 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Olema Pharmaceuticals Q3 2026 Earnings FAQ Did Olema Pharmaceuticals beat earnings estimates for Q3 2026? Olema Pharmaceuticals (NASDAQ:OLMA) reported earnings of -$0.73 per share for Q3 2026, missing the consensus estimate of -$0.6368. The report was announced on Tuesday, November 10, 2026. Olema Pharmaceuticals Earnings HeadlinesOlema Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 20261 hour ago | marketscreener.comMOlema Oncology Reports Third Quarter 2026 Financial and Operating ResultsNovember 10 at 7:00 AM | globenewswire.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)Olema Pharmaceuticals (OLMA) Projected to Post Earnings on MondayNovember 8 at 1:56 AM | americanbankingnews.comOlema Oncology to Present Combination Data from the Palazestrant and OP-3136 Programs at the 2026 San Antonio Breast Cancer SymposiumNovember 5, 2026 | markets.businessinsider.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 3, 2026 | globenewswire.comSee More Olema Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Olema Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Olema Pharmaceuticals and other key companies, straight to your email. Email Address About Olema PharmaceuticalsOlema Pharmaceuticals (NASDAQ:OLMA) is a clinical-stage biopharmaceutical company focused on developing therapies for women’s cancers, particularly breast cancer. The company’s research centers on treatments that target pathways involved in hormone-sensitive tumors. Its lead candidate, palazestrant (OP-1250), is an oral therapy designed to act as both a selective estrogen receptor degrader and a complete estrogen receptor antagonist. Olema has studied it as a potential treatment for estrogen receptor–positive breast cancer, including in combination with other cancer medicines. The company is also developing OP-3136, an investigational candidate targeting KAT6 proteins. Olema does not have marketed products; its work is focused on research and clinical development. The company was founded by Sean Biller, who has served as its chief executive officer.View Olema Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
